StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)

Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%

AbbVie operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AbbVie's operating income for the twelve months ending Jun 30, 2026 was $16.87B, up 53.8% year over year. For fiscal 2025 it was $15.08B, up 65.0% from the year before. Over ten years it grew 7.2% a year on average. The highest annual figure on record is $18.12B in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.08B+65.0%
FY2024Dec 31, 2024$9.14B-28.4%
FY2023Dec 31, 2023$12.76B-29.6%
FY2022Dec 31, 2022$18.12B+1.1%
FY2021Dec 31, 2021$17.92B+57.7%
FY2020Dec 31, 2020$11.36B-12.5%
FY2019Dec 31, 2019$12.98B+103.4%
FY2018Dec 31, 2018$6.38B-33.1%
FY2017Dec 31, 2017$9.55B+2.2%
FY2016Dec 31, 2016$9.34B+23.9%
FY2015Dec 31, 2015$7.54B+121.0%
FY2014Dec 31, 2014$3.41B-39.8%
FY2013Dec 31, 2013$5.66B-2.6%
FY2012Dec 31, 2012$5.82B+60.7%
FY2011Dec 31, 2011$3.62B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.43B+31.4%
Q1 FY2026Mar 31, 2026$3.99B+6.9%
Q4 FY2025Dec 31, 2025$4.54B–
Q3 FY2025Sep 30, 2025$1.90B-50.3%
Q2 FY2025Jun 30, 2025$4.89B+22.4%
Q1 FY2025Mar 31, 2025$3.73B+33.4%
Q4 FY2024Dec 31, 2024-$1.49B-146.6%
Q3 FY2024Sep 30, 2024$3.83B+68.0%
Q2 FY2024Jun 30, 2024$4.00B-11.4%
Q1 FY2024Mar 31, 2024$2.80B+1.1%
Q4 FY2023Dec 31, 2023$3.20B-41.9%
Q3 FY2023Sep 30, 2023$2.28B-50.4%
Q2 FY2023Jun 30, 2023$4.51B+37.0%
Q1 FY2023Mar 31, 2023$2.77B-41.3%
Q4 FY2022Dec 31, 2022$5.50B+8.4%
Q3 FY2022Sep 30, 2022$4.60B+6.9%
Q2 FY2022Jun 30, 2022$3.30B-25.8%
Q1 FY2022Mar 31, 2022$4.72B+15.0%
Q4 FY2021Dec 31, 2021$5.07B+35.2%
Q3 FY2021Sep 30, 2021$4.31B+32.3%
Q2 FY2021Jun 30, 2021$4.44B+490.6%
Q1 FY2021Mar 31, 2021$4.10B+13.9%
Q4 FY2020Dec 31, 2020$3.75B-5.1%
Q3 FY2020Sep 30, 2020$3.26B+24.4%
Q2 FY2020Jun 30, 2020$752.00M-77.9%
Q1 FY2020Mar 31, 2020$3.60B+19.7%
Q4 FY2019Dec 31, 2019$3.96B–
Q3 FY2019Sep 30, 2019$2.62B-17.2%
Q2 FY2019Jun 30, 2019$3.40B+23.1%
Q1 FY2019Mar 31, 2019$3.01B+3.7%
Q4 FY2018Dec 31, 2018-$2.44B-237.0%
Q3 FY2018Sep 30, 2018$3.16B+17.3%
Q2 FY2018Jun 30, 2018$2.76B+3.8%
Q1 FY2018Mar 31, 2018$2.90B+20.6%
Q4 FY2017Dec 31, 2017$1.78B-23.0%
Q3 FY2017Sep 30, 2017$2.69B+14.1%
Q2 FY2017Jun 30, 2017$2.66B–
Q1 FY2017Mar 31, 2017$2.41B–
Q4 FY2016Dec 31, 2016$2.31B–
Q3 FY2016Sep 30, 2016$2.36B–

More AbbVie figures

See a number that looks wrong?